These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9112487)

  • 1. Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
    Litwin MS; Fine JT; Dorey F; Figlin RA; Belldegrun AS
    J Urol; 1997 May; 157(5):1608-12. PubMed ID: 9112487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life outcomes after brachytherapy for early stage prostate cancer.
    Brandeis JM; Litwin MS; Burnison CM; Reiter RE
    J Urol; 2000 Mar; 163(3):851-7. PubMed ID: 10687991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
    Wagner JR; Walther MM; Linehan WM; White DE; Rosenberg SA; Yang JC
    J Urol; 1999 Jul; 162(1):43-5. PubMed ID: 10379736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 11. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA
    Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quality of life in patients with renal carcinoma].
    Vukotić-Maletić V; Stojković-Djordjević B; Hadzi-Djokić J; Dragićević D
    Acta Chir Iugosl; 1999; 46(1 Suppl):15-8. PubMed ID: 10951771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
    J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life among haemodialysis patients--relationship with clinical indicators, morbidity and mortality.
    Morsch CM; Gonçalves LF; Barros E
    J Clin Nurs; 2006 Apr; 15(4):498-504. PubMed ID: 16553764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer.
    Bacon CG; Giovannucci E; Testa M; Kawachi I
    J Urol; 2001 Nov; 166(5):1804-10. PubMed ID: 11586228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
    Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
    Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 20. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms.
    Hammerlid E; Taft C
    Br J Cancer; 2001 Jan; 84(2):149-56. PubMed ID: 11161369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.